Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

13.53 -0.28 (-2.03%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 23, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	895,749
Open	14.17
Bid (Size)	13.55 (300)
Ask (Size)	13.56 (100)
Prev. Close	13.81
Today's Range	13.52 - 14.44
52wk Range	3.110 - 17.49
Shares Outstanding	67,176,067
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Amylyx (AMLX) Q4 2025 Earnings Call Transcript ↗

March 03, 2026

Amylyx (AMLX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Narrower-Than-Expected Q4 Loss, Focus Remains on Key 2026 Data ↗

March 03, 2026

Via Chartmill

Performance

YTD	+18.5%	+18.5%
1 Month	-3.4%	-3.4%
3 Month	+8.2%	+8.2%
6 Month	+1.7%	+1.7%
1 Year	+257.9%	+257.9%

More News

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

March 03, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

February 26, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗

February 25, 2026

Via The Motley Fool

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗

February 25, 2026

Via The Motley Fool

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗

February 25, 2026

Via The Motley Fool

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

February 24, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million ↗

February 01, 2026

Via The Motley Fool

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

January 08, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗

December 09, 2025

Via The Motley Fool

Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗

December 09, 2025

Via The Motley Fool

Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗

December 09, 2025

Via The Motley Fool

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

December 05, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗

December 03, 2025

Via The Motley Fool

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗

November 17, 2025

Via The Motley Fool

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗

November 17, 2025

Via The Motley Fool

Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗

November 17, 2025

Via The Motley Fool

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗

November 17, 2025

Via The Motley Fool

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

November 13, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

November 11, 2025

From Rosen Law Firm

Via Business Wire

Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Avantor, Inc. (NYSE: AVTR); Humana Inc. (NYSE: HUM); and Maison Solutions Inc. (NASDAQ: MSS): Grabar Law Office Investigates Claims on Your Behalf

November 06, 2025

From Grabar Law Office

Via GlobeNewswire

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Narrows Q3 2025 Loss, Bolsters Cash Runway to 2028 ↗

November 06, 2025

Via Chartmill

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

November 06, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Amylyx Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Amylyx Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Amylyx Pharmaceuticals, Inc. - Common Stock trade on?

Amylyx Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock is AMLX on the Nasdaq Stock Market

What is the current price of Amylyx Pharmaceuticals, Inc. - Common Stock?

The current price of Amylyx Pharmaceuticals, Inc. - Common Stock is 13.53

When was Amylyx Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Amylyx Pharmaceuticals, Inc. - Common Stock was at 03/23/26 04:00 PM ET

What is the market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock is 908.89M

How many shares of Amylyx Pharmaceuticals, Inc. - Common Stock are outstanding?

Amylyx Pharmaceuticals, Inc. - Common Stock has 909M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.